Navigation Links
Amicus Therapeutics to Present at Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011
Date:5/31/2011

CRANBURY, N.J., May 31, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Matthew R. Patterson, President and Acting Chief Executive Officer, will present a corporate overview at the Jefferies 2011 Global Healthcare Conference in New York, NY on Tuesday, June 7 at 12:15 p.m. ET.

A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days. Participants are encouraged to visit the web site 10 minutes prior to the start of the presentation to register, download and install any necessary software.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program Amigal(tm) (migalastat HCl) is in Phase 3 for the treatment of Fabry disease.

FOLD-G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Amicus Therapeutics Announces First Quarter 2011 Financial Results and Continued Progress of Development Programs
2. Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman
3. Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
4. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
5. Amicus Therapeutics to Present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011
6. Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinsons Disease
7. Amicus Therapeutics Announces Third Quarter 2010 Financial Results
8. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
9. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
10. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
11. Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... DIEGO , Dec. 9, 2016 aTyr Pharma, Inc. ... discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, ... at the upcoming BMO Prescriptions for Success Healthcare Conference at the ... on Wednesday, December 14, 2016, at 4:20 p.m. ET. ... ...
(Date:12/9/2016)... , Dec. 9, 2016  Axovant Sciences Ltd. ... biopharmaceutical company focused on the treatment of dementia, ... from a Phase 2b trial evaluating treatment with ... compared with donepezil plus placebo in people with ... addition of intepirdine to treatment was associated with ...
(Date:12/8/2016)... , Dec. 8, 2016 Australia Glaucoma ... GlobalData,s new report, "Australia Glaucoma Surgery Devices ... on the Australia Glaucoma Surgery Devices market. The ... volume (in units) and average prices (USD) within ... report also provides company shares and distribution shares ...
Breaking Medicine Technology:
(Date:12/9/2016)... NY (PRWEB) , ... December 09, 2016 , ... ... and Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits ... and the District of Columbia as an education tool in the war against teen ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... Pierre Hotel in New York, NY, on December 3rd, to benefit Holy Name ... attended the annual event, which raised over $1 million - the largest event ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Quality Insights beginning January 1, 2017. The name change aligns the entire ... measuring and improving health care quality. , “We are very proud of the ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
Breaking Medicine News(10 mins):